281 related articles for article (PubMed ID: 2850460)
1. Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism. In vivo studies.
Gardin JP; Patron P; Fouqueray B; Prigent A; Paillard M
Miner Electrolyte Metab; 1988; 14(4):221-8. PubMed ID: 2850460
[TBL] [Abstract][Full Text] [Related]
2. In vivo studies of parathyroid gland function in secondary hyperparathyroidism.
Salusky IB; Goodman WG
Adv Nephrol Necker Hosp; 1996; 25():289-302. PubMed ID: 8717632
[TBL] [Abstract][Full Text] [Related]
3. Serum ionized calcium, nephrogenous and total urinary cyclic AMP and urinary phosphate in normal subjects.
Thode J; Holmegaard SN; Siggaard-Andersen O
Scand J Clin Lab Invest; 1984 Apr; 44(2):111-8. PubMed ID: 6326252
[TBL] [Abstract][Full Text] [Related]
4. Disturbance of basal and stimulated serum levels of intact parathyroid hormone in primary hyperparathyroidism.
Ljunghall S; Larsson K; Lindh E; Lindqvist U; Rastad J; Akerström G; Wide L
Surgery; 1991 Jul; 110(1):47-53. PubMed ID: 1907770
[TBL] [Abstract][Full Text] [Related]
5. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P
Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of the determination of nephrogenous cyclic AMP in the diagnosis of primary hyperparathyroidism].
Bill G; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1983 Mar; 113(9):327-30. PubMed ID: 6302835
[TBL] [Abstract][Full Text] [Related]
7. Functional recovery of the parathyroid glands after surgery for primary hyperparathyroidism.
Bergenfelz A; Valdermarsson S; Ahrén B
Surgery; 1994 Nov; 116(5):827-36. PubMed ID: 7940185
[TBL] [Abstract][Full Text] [Related]
8. Abnormal responsiveness of nephrogenous cyclic AMP excretion following intravenously administered calcium in normocalcaemic squamous cell cancer patients.
Naafs MA; Hackeng WH; Koorevaar G; Silberbusch J
Bone Miner; 1988 Jul; 4(3):289-98. PubMed ID: 2847840
[TBL] [Abstract][Full Text] [Related]
9. Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism.
Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Rodriguez AP; Felsenfeld AJ
J Bone Miner Res; 1997 Mar; 12(3):347-55. PubMed ID: 9076577
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.
Broadus AE; Mahaffey JE; Bartter FC; Neer RM
J Clin Invest; 1977 Oct; 60(4):771-83. PubMed ID: 197123
[TBL] [Abstract][Full Text] [Related]
11. Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism.
Bergenfelz A; Lindblom P; Lindergård B; Valdemarsson S; Westerdahl J
World J Surg; 2003 Apr; 27(4):481-5. PubMed ID: 12658497
[TBL] [Abstract][Full Text] [Related]
12. [Suppressibility of parathyroid function in primary hyperparathyroidism as estimated by nephrogenous cyclic AMP (author's transl)].
Sohn HE; Yumita S; Unakami H; Miura R; Furukawa Y
Nihon Naibunpi Gakkai Zasshi; 1982 Feb; 58(2):110-21. PubMed ID: 6282661
[TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. Reelevation of parathyroid hormone level after parathyroidectomy in patients with primary hyperparathyroidism: importance of decreased renal parathyroid hormone sensitivity.
Yamashita H; Noguchi S; Moriyama T; Takamatsu Y; Sadanaga K; Uchino S; Watanabe S; Ogawa T
Surgery; 2005 Apr; 137(4):419-25. PubMed ID: 15800489
[TBL] [Abstract][Full Text] [Related]
15. The dependency of calcium set point on basal plasma calcium in dialysis patients: a better explanation for the discrepancies regarding its link with PTH secretion than methodological differences.
Hardy-Yverneau P; Shenouda M; Moriniere P; Legallais C; Brazier M; Achard J; Fournier A
Clin Nephrol; 1998 Oct; 50(4):236-46. PubMed ID: 9799069
[TBL] [Abstract][Full Text] [Related]
16. [Hyperparathyroidism with lithium].
Brochier T; Adnet-Kessous J; Barillot M; Pascalis JG
Encephale; 1994; 20(3):339-49. PubMed ID: 8088238
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenous cyclic adenosine monophosphate levels in normocalcemic cancer patients: its significance.
Abramson EC; Kukreja SC; Lad TE; Shemerdiak WP; York PA
Horm Metab Res; 1984 Apr; 16(4):204-7. PubMed ID: 6327481
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenous cyclic AMP as a parathyroid function test.
Broadus AE
Nephron; 1979; 23(2-3):136-41. PubMed ID: 220548
[TBL] [Abstract][Full Text] [Related]
19. Normocalcemic primary hyperparathyroidism: resistance to PTH effect on tubular reabsorption of calcium.
Gardin JP; Paillard M
Miner Electrolyte Metab; 1984; 10(5):301-8. PubMed ID: 6493158
[TBL] [Abstract][Full Text] [Related]
20. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism.
Ramirez JA; Goodman WG; Gornbein J; Menezes C; Moulton L; Segre GV; Salusky IB
J Clin Endocrinol Metab; 1993 Jun; 76(6):1489-94. PubMed ID: 8501155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
